VEGFB and type 2 diabetes mellitus: In rodent models of dyslipidemia, pre‐diabetes, or T2DM, deficiency or pharmacological inhibition of VEGF‐B ameliorates ectopic lipid tissue accumulation, correlating with improved insulin sensitivity and glucose handling 17, 18, 19.